Feasibility and outcomes of percutaneous thermal ablation of hepatocellular carcinoma in a transplanted allograft.

PURPOSE: To examine the safety, feasibility, and oncologic control following percutaneous image-guided thermal ablation of hepatocellular carcinoma (HCC) in a transplanted allograft. MATERIALS AND METHODS: Retrospective review was performed to identify patients who underwent liver transplantation for HCC and subsequently underwent percutaneous hepatic thermal ablation for recurrent HCC within the allograft between January 1st, 2000-September 1st, 2016. Eleven patients with hepatic allograft HCC underwent twelve percutaneous thermal ablation procedures to treat 16 lesions. Patient, procedural characteristics, and local oncologic efficacy were reviewed. Complications were characterized via the Common Terminology for Clinically Adverse Events nomenclature [CTCAE] v4.03). RESULTS: Eleven transplant recipients underwent treatment of 16 HCC tumors in their allografts during 12 ablation sessions. Mean follow-up time was 25 months (range 2-96 months). Local oncologic control was achieved in 10 of 11 tumors (91%) with imaging follow-up. One patient (8%) with Roux-en-Y biliary reconstruction developed a major complication with hepatic abscess. CONCLUSION: Thermal ablation of recurrent HCC in transplanted allografts can be accomplished safely with acceptable rates of local control for patients with duct-to-duct biliary reconstruction. Due to the high number of patients deemed surgically unresectable, the morbidity of surgical resection, the side effects of targeted therapies, and significant mortality associated with recurrences in the transplanted allograft, patients may benefit from percutaneous thermal ablative treatments. Further study is needed to assess the role of thermal ablation in allograft HCC recurrences as primary therapy or in a multimodality approach with emerging systemic therapies.

Preoperative chemoembolization in patients with hepatocellular carcinoma undergoing liver transplantation: influence of emergent versus elective procedures on patient survival and tumor recurrence rate.

Our purpose was to compare the recurrence rate and survival in patients with hepatocellular carcinoma (HCC) who had elective transarterial chemoembolization (TACE), immediate preoperative TACE, or no treatment prior to orthotopic liver transplantation (OLT). A total of 132 patients with HCC had TACE prior to OLT. Eighteen patients had no TACE before OLT and functioned as a control group. The urgent group included 35 patients embolized less than 24 h before OLT and the elective group included 97 patients embolized greater than 1 day before transplantation. These groups were compared with regard to tumor staging, hepatic synthetic function, and post-TACE tumor necrosis and survival and recurrence rates. Patients were followed for a mean of 780 days post OLT (1-2912 days). The tumor staging was similar between groups but the Childs-Pugh score in the urgent and untreated group was significantly higher than that of the other groups. The degree of necrosis at explant was also significantly different between the two treated groups, with an average 35% necrosis in the patients embolized less than 24 h before OLT vs 77% in the elective group (p < 0.002). Recurrence rate in the urgent group was 8 of 35 (23%) in a median of 580 days, 20 of 97 (21%) in a median of 539 days in the elective group, and 2 of 18 (11%) in a median of 331 days in the no-TACE group. Survival at 1, 3, and 5 years was 91%, 80%, and 72% in the elective group, 79%, 58%, and 39% in the urgent group, and 69%, 61%, and 41% in the no-TACE group, respectively. The urgent and no-TACE groups had significantly worse survival compared with the other groups; however, the tumor recurrence rates were statistically the same among all three groups. TACE within 24 h of OLT causes an average of 35% necrosis and elective TACE increases necrosis further to 77%. Despite this difference, the tumor recurrence rate in the three groups is equivalent and no different from that in the group that received no treatment before OLT. The decreased survival in the immediate and no-TACE groups was due to non-cancer-related deaths.

Midterm outcome of endovascular abdominal aortic aneurysm repair in octogenarians: a single institution's experience.

OBJECTIVES: We analyzed midterm durability of endovascular abdominal aortic aneurysm repair (EVAR) in octogenarians compared with younger patients. METHODS: Data for 182 consecutive patients who underwent elective EVAR between 1999 and 2003 were retrospectively reviewed. Forty-nine patients (27%) were 80 years or older (study group [SG]; mean age, 84 years; range, 80-89 years), and 133 patients (73%) were younger (control group [CG]; mean age, 72 years; range, 53-79 years). Chi2 analysis, Fisher exact test, Student t test, and Mann-Whitney U test were used as appropriate to test for intergroup differences. Kaplan-Meier curves, log-rank tests, and multivariate Cox models were used for time-to-event analysis, with P < or =.05 considered significant. RESULTS: Mean follow-up was 16 months (range, 1-43 months). Body weight was higher (P <.001), and elevated plasma lipid levels (59% vs 43%; P =.042) and use of nicotine (47% vs 29%; P =.015) more frequent in the octogenarians. Baseline aneurysm size, procedure-related data, and hospital stay were comparable between groups. Aneurysm-related mortality was 0% in the study group and 0.7% in the control group (P =.740). Systemic complications occurred in 22% (SG) versus 11% (CG) (P =.035), owing to a rise in serum creatinine concentration greater than 30% of baseline in 14% in the octogenarian group (vs 5% in the CG; P =.048). Groin lymphoceles developed in 12% (SG) versus 2% (CG; P =.013). Technical success was 96% (SG) versus 98% (CG; P =.408), and clinical success was 86% versus 90% (P =.269). No aneurysm rupture occurred during follow-up, and aneurysm-related adverse events were comparable between groups. The estimated risk for any type of endoleak (2.2; 95% confidence interval [CI], 1.1-4.2; P =.023) or type II endoleak (2.1; 95% CI, 1.0-4.3; P = 0.51) was higher in the study group versus the control group; however, this did not affect secondary procedure rates (SG 16% vs CG 12%; estimated risk, SG vs CG,: 1.5; 95% CI, 0.6-3.6; P = 0.420) or aneurysm remodeling (97.2% combined aneurysm sac stabilization or decrease in both groups; P =.592). Aneurysm enlargement occurred in 2.8% (SG 1 vs CG 4; P =.592). CONCLUSION: Elective EVAR in octogenarians appears safe and effective over midterm follow-up, with a temporary decrease in renal function (14%) and postoperative lymphoceles (12%) being the most common postoperative adverse events. Advanced chronologic age is not associated with diminished procedural outcome, clinical success, or postoperative survival, compared with younger age. Because of low perioperative mortality and high procedural success, EVAR may be the preferred approach to abdominal aortic aneurysm treatment in selected elderly patients.

Endovascular therapy of iliac arteries: routine application of intraluminal stents does not improve clinical patency.

Our objective in this study was to review our experience with endovascular therapy of iliac artery occlusive disease over the past decade, and to compare the results of angioplasty alone with the addition of endovascular stents to these procedures. This report details a retrospective analysis of clinical data on 141 consecutive patients with iliac artery occlusive disease, treated by balloon angioplasty alone, or with the addition of intraluminal stents. The procedures analyzed included 58 common iliac artery interventions (26 angioplasties and 32 stent insertions) and 83 external iliac artery procedures (43 angioplasties and 40 stent insertions). Early and continued success, and their components, are reported and compared according to published standards. While endovascular therapy of iliac artery occlusive disease is effective in relieving symptoms, clinical patency rates are lower than those reported for direct reconstruction. Primary stent placement has not enhanced clinical patency in the iliac arteries, and the selective insertion of these devices for more complicated angioplasty procedures seems warranted.

Interventional procedures in the intensive care unit patient.

Image-guided interventional techniques have markedly altered the management of many cardiothoracic problems in the intensive care unit. These techniques are less invasive, more patient friendly, and cost-effective. This article covers venous line placement and management, transpleural and transpulmonary biopsy and drainage procedures and interventions for variceal bleeding, massive hemoptysis, massive pulmonary embolism, and veno-occlusive disease.